Dual hypocretin receptor antagonism enhances sleep and nursing behavior in lactating rats.

Abstract

Hypocretins (also known as orexins) are neuropeptides that regulate the sleep-wake cycle and modulate various behaviors, including maternal behavior. They act through two receptor subtypes: hypocretin receptor 1 (HcrtR1) and hypocretin receptor 2 (HcrtR2). Although Dual Orexin Receptor Antagonists (DORAs) are clinically used as hypnotics, most preclinical studies with these drugs have been conducted in males, with limited research in females, leaving the postpartum period largely unexplored. Here, we examined the impact of the DORA Suvorexant on sleep and maternal behavior in lactating rats. Lactating and virgin female rats were implanted with electrodes for polysomnographic recording. Using a counterbalanced design, Suvorexant was orally administered at doses of 0, 10 (SUV10), and 30 mg/kg (SUV30) to virgin rats in diestrus and to lactating rats between postpartum days 4 and 8. Sleep recordings and maternal behaviors were assessed during the light phase for six hours following the administration of the drug. Suvorexant reduced wakefulness and increased slow wave sleep, intermediate state, and REM sleep in both groups, with a stronger effect in virgin females. In lactating rats, Suvorexant increased nursing time and milk ejections, while reducing active maternal behavior such as pup-licking. These findings demonstrate that dual hypocretin receptor antagonism produces hypnotic effects and selectively modulates maternal behavior, promoting nursing while reducing active maternal behavior.